



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/715,983	11/20/2000	Brett P. Monia	ISPH-0519	6803
34138	7590	08/25/2004	EXAMINER	
COZEN O'CONNOR, P.C. 1900 MARKET STREET PHILADELPHIA, PA 19103-3508				ZARA, JANE J
ART UNIT		PAPER NUMBER		
		1635		

DATE MAILED: 08/25/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	09/715,983	Applicant(s)	MONIA ET AL.
Examiner	Jane Zara	Art Unit	1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 November 2003.
2a) This action is FINAL. 2b) This action is non-final.
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 24,26-28,30 and 31 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 24,26-28,30 and 31 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6-18-04.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) Notice of Informal Patent Application (PTO-152)
6) Other: _____.

DETAILED ACTION

This Office action is in response to the communications filed on 7-7-03 and 11-7-03.

Claims 24, 26-28, 30 and 31 are pending in the instant application.

The finality of the Office action mailed 5-7-03 is hereby withdrawn upon further consideration and in light of the new rejection set forth below.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 24, 26-28, 30 and 31 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of decreasing blood glucose and insulin levels in a human comprising administering the antisense compound of SEQ ID NO: 56 (ISIS 131410), does not reasonably provide enablement for a method of decreasing blood glucose and insulin levels in a human comprising the administration of any antisense compound between 8-30 nucleobases in length that specifically hybridizes with and inhibits expression of human PI3Kp85 of SEQ ID NO: 1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and or use the invention commensurate in scope with these claims.

The claims are drawn to a method of decreasing blood glucose and insulin levels in a human comprising the administration of any antisense compound between 8-30 nucleobases in length that specifically hybridizes with and inhibits the expression of human PI3Kp85 of SEQ ID NO: 1. The following factors have been considered in determining that the specification does not enable the skilled artisan to make and/or use the invention over the scope claimed.

The state of the prior art and the predictability or unpredictability of the art. The following references are cited herein to illustrate the state of the art of antisense treatment in organisms. Branch and Crooke teach that the *in vivo* (whole organism) application of nucleic acids (such as antisense) is a highly unpredictable endeavor due to target accessibility and delivery issues. Crooke also points out that cell culture examples are generally not predictive of *in vivo* inhibition of target genes. (See entire text for Branch and especially pages 34-36 for Crooke).

Likewise, Peracchi cautions investigators in the field of gene therapy about the problems of achieving *in vivo* efficacy using oligonucleotide based approaches: "Much progress has been made towards understanding the structure and mechanism of these catalysts [ribozymes]... Despite this, it is not yet clear whether these molecules can be developed into clinically useful pharmaceutical preparations." (See the abstract on page 47). Peracchi cites stability and delivery obstacles that need to be overcome in achieving desired *in vivo* efficacy: "A crucial limit of ribozymes in particular, and of oligonucleotide-based drugs in general, lies in their intrinsically low ability to cross biological

membranes, and therefore to enter the cells where they are supposed to operate...cellular uptake following systemic administration appears to require more sophisticated formulations... the establishment of delivery systems that mediate efficient cellular uptake and sustained release of the ribozyme remains one of the major hurdles in the field." (See text on page 51).

Tamm et al, in a review article discussing the therapeutic potential of antisense in treating various forms of neoplasia, conclude that "Proof of clinical efficacy, of any of the antisense oligonucleotides in the field of oncology, is still missing." (see especially pages 490-493 for a summary of various clinical trials in process using antisense). Additionally, Agrawal et al point to various factors contributing to the unpredictability of antisense therapy, including non-antisense effects attributed to secondary structure and charge, as well as biological effects exerted by sequence motifs existing within the antisense sequences, all providing for unpredictable in vivo side effects and limited efficacy (e.g. see pages 72-76). Agrawal et al speak to the unpredictable nature of the antisense field thus: "It is therefore appropriate to study each antisense oligonucleotide in its own context, and relevant cell line, without generalizing the results for every oligonucleotide." (see page 80). Cellular uptake of antisense oligonucleotides by appropriate target cells is another rate limiting step that has yet to be overcome in achieving predictable clinical efficacy using antisense. Both Chirila et al and Agrawal et al point to the current limitations which exist in our understanding of the cellular uptake of antisense oligonucleotides in vitro and in vivo (see Agrawal et al especially at pages 79-80; see Chirila et al in its entirety, especially pages 326-

327 for a general review of the “important and inordinately difficult challenge” of the delivery of therapeutic antisense oligonucleotides to target cells).

The amount of direction or guidance presented in the specification AND the presence or absence of working examples. Applicants have not provided guidance in the specification toward a method of decreasing blood glucose or insulin levels in a subject comprising the administration of a representative number of antisense oligonucleotides between 8 and 30 nucleobases that specifically hybridize and inhibit the expression of SEQ ID NO: 1, encoding pI3K p85 in vivo and further whereby blood glucose and insulin levels are decreased in that subject. The specification teaches a method of decreasing blood glucose or insulin levels in a subject comprising the administration of the antisense oligonucleotide of SEQ ID NO: 56 (a.k.a. ISIS 131410). One skilled in the art would not accept on its face the example given in the specification of the method of decreasing blood glucose or insulin levels in a subject comprising the administration of the antisense oligonucleotide of SEQ ID NO: 56 as being correlative or representative of the ability to provide these treatment effects using any antisense between 8 and 30 nucleobases that specifically hybridizes and inhibits the expression of SEQ ID NO: 1, encoding pI3K p85, in view of the lack of guidance in the specification and known unpredictability associated with inhibition of a target gene in an organism using antisense and further whereby the treatment effects of reducing blood glucose and insulin levels are provided in that subject.

The breadth of the claims and the quantity of experimentation required. The claims are drawn to a method of decreasing blood glucose and insulin levels in a human comprising the administration of any antisense compound between 8-30 nucleobases in length that specifically hybridizes with and inhibits the expression of human PI3Kp85 of SEQ ID NO: 1. The quantity of experimentation required to practice the invention as claimed would require the *de novo* determination of accessible target sites, modes of delivery and formulations to target appropriate cells and /or tissues harboring the target pI3K p85 using any antisense between 8-30 nucleobases that specifically targets SEQ ID NO: 1, whereby pI3K p85 expression is inhibited in cells *in vivo* and decreased blood glucose and insulin levels are observed in that subject. Since the specification fails to provide any particular guidance for a representative number of antisense oligonucleotides that specifically target SEQ ID NO: 1 and inhibit its expression *in vivo*, and further where treatment effects are provided using a representative number of antisense, and since determination of these factors is highly unpredictable, it would require undue experimentation to practice the invention over the scope claimed.

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax

Art Unit: 1635

telephone number for the Group is **703-872-9306**. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (571) 272-0760. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

JZ
8-15-04

JOHN L. LEGUYADER
SUPERVISOR
TECHNOLOGY CENTER 1600
MINER